Please feel free to contact us with case reports highlighting the use of afatinib in patients with advanced or metastatic NSCLC with uncommon EGFR mutations. The cases must have been published in a peer-reviewed journal or presented at a congress.
Disclaimer
You are leaving the Uncommon EGFR Mutations website. You are being directed to a third-party website. This link is provided for your convenience. Please note that the third-party website is not under the control of the Boehringer Ingelheim Corporation and not subject to the privacy policy of this website.
Do you want to continue ?
